IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11970541 B1

PDFFull Text
Date of Patent:
Apr. 30, 2024

Filed:

Nov. 19, 2021

Anti-cd20 antibody

Applicant:

Beijing Mabworks Biotech Co. Ltd., Beijing, CN;

Inventors:

Feng Li, Beijing, CN;

Boyan Zhang, Foster City, CA (US);

Pei Ye, Lawrenceville, GA (US);

Assignee:

BEIJING MABWORKS BIOTECH CO. LTD., Beijing, CN;

Attorneys:

Perkins Coie LLP

Viola T. Kung

Primary Examiner:

Sharon X Wen

Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/00 (2006.01); A61P 37/02 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 37/00 (2018.01); A61P 37/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/90 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.

Find Patent Forward Citations

Loading…